Thrombocytopenia in the ICU: disseminated intravascular coagulation and thrombotic microangiopathies —what intensivists need to know
Condition: Primary Immune Thrombocytopenia Interventions: Drug: Placebo; Drug: TAK-079 Sponsor: Millennium Pharmaceuticals, Inc. Not yet recruiting
Traditional coil embolization slows blood flow to enable hemostasis. Sufficient platelet activation and intact coagulation cascade are required for hemostasis. Past studies have found that thrombocytopenia and/or coagulopathy are factors associated with failure of embolization to stop bleeding. Glue embolization is thought to not be affected by such factors to stop bleeding. To evaluate the efficacy of glue embolization to other forms of embolization, we retrospectively reviewed all emergent embolizations performed for bleeding.
Lusutrombopag is an oral, small molecule thrombopoietin receptor agonist approved in Japan and US for treatment of thrombocytopenia (TCP), and in EU for severe TCP, associated with chronic liver disease (CLD) in patients undergoing planned invasive procedures. The degree of TCP may impact treatment response to lusutrombopag and the need for platelet transfusion (PT). This analysis evaluates the increase in platelet count (PC) and maximum PC achieved according to baseline PC.
Lusutrombopag (LUSU) is a thrombopoietin receptor agonist (TPO-RA) approved in Japan and US for treatment of thrombocytopenia (TCP), and in EU for severe TCP, associated with chronic liver disease (CLD) in patients undergoing planned invasive procedures (IP). TPO-RAs have been associated with increased risk of thrombotic events in patients with CLD and a safety assessment of new agents is critical. LUSU safety was assessed in a pooled retrospective analysis of three clinical studies.
Lusutrombopag (LUSU) is an oral, small molecule thrombopoietin receptor agonist approved in Japan and US for treatment of thrombocytopenia (TCP), and in EU for severe TCP, associated with chronic liver disease (CLD) in patients undergoing planned invasive procedures (IPs). This integrated analysis assessed the consistency of the efficacy and safety of LUSU clinical trial data across a larger population.
We present a 15-year-old boy with Evans syndrome and common variable immunodeficiency who experienced a severe, refractory flare 16 months postsplenectomy. After failing to respond to multiple other agents, he achieved a durable response to a bortezomib-based regimen. Bortezomib may be a reasonable second or third line option, especially before high-morbidity therapies such as splenectomy or stem cell transplantation.
We report the outcome of ELT therapy in 4 children who were treated for rare hematologic disorders, including Pearson syndrome, DiGeorge syndrome, posttransplant allogeneic poor graft function (PGF), and Wiskott-Aldrich syndrome. The ELT tolerance in the analyzed group was good, with the exception of the child with Pearson syndrome, who experienced an exacerbation of cataracts and had to discontinue treatment. Thromboembolic events were observed in one child, who continued ELT therapy despite achieving normalized platelet counts. Independence from PLT transfusions was observed at the 4-week timepoint of therapy in patients...
Authors: Yoo IY, Kim JY, Yoon YK, Huh HJ, Lee NY Abstract The recent increase in severe fever with thrombocytopenia syndrome (SFTS) cases has led to the development of the SFTS-QS kit (MiCoBioMed, Seongnam, Korea) for detecting the SFTS virus (SFTSV, now renamed Huaiyangshan banyangvirus). SFTS-QS is a qualitative real-time reverse transcription PCR assay based on lab-on-a-chip technology. We evaluated the performance of the SFTS-QS kit and compared it with that of the PowerChek SFTSV Real-time PCR kit (PowerChek; Kogene Biotech, Seoul, Korea). A total of 117 serum samples were simultaneously assayed using the SFTS...
Publication date: 18 February 2020Source: Cell Reports, Volume 30, Issue 7Author(s): Chao Chen, Ming-an Sun, Claude Warzecha, Mahesh Bachu, Anup Dey, Tiyun Wu, Peter D Adams, Todd Macfarlan, Paul Love, Keiko OzatoSummaryHIRA is a histone chaperone that deposits the histone variant H3.3 in transcriptionally active genes. In DiGeorge syndromes, a DNA stretch encompassing HIRA is deleted. The syndromes manifest varied abnormalities, including immunodeficiency and thrombocytopenia. HIRA is essential in mice, as total knockout (KO) results in early embryonic death. However, the role of HIRA in hematopoiesis is poorly understood...
Condition: Primary Immune Thrombocytopenia (ITP) Interventions: Biological: efgartigimod; Other: Placebo Sponsor: argenx BVBA Not yet recruiting